Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: Ultrasensitive bioassaying of HER-2 protein for diagnosis of breast cancer using reduced graphene oxide/chitosan as nanobiocompatible platform

Fig. 4

a The ECL curves for GCE/rGO/CS-[Ru(bpy)3]2+/Ab-HER-2 in optimized conditions (pH = 8.2, PBS solution, RT) for different concentrations of HER-2 protein (0.000001, 0.00001, 0.0001, 0.001, 0.01, 0.1 and 1 nM); b calibration curve, the ECL intensity of final modified electrode at the corresponding concentrations of HER-2 protein

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us